KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Revenue (2016 - 2025)

Nektar Therapeutics has reported Revenue over the past 16 years, most recently at $21.8 million for Q4 2025.

  • Quarterly results put Revenue at $21.8 million for Q4 2025, down 25.25% from a year ago — trailing twelve months through Dec 2025 was $55.2 million (down 43.89% YoY), and the annual figure for FY2025 was $55.2 million, down 43.89%.
  • Revenue for Q4 2025 was $21.8 million at Nektar Therapeutics, up from $11.8 million in the prior quarter.
  • Over the last five years, Revenue for NKTR hit a ceiling of $29.2 million in Q4 2024 and a floor of $10.5 million in Q1 2025.
  • Median Revenue over the past 5 years was $23.6 million (2022), compared with a mean of $21.9 million.
  • Biggest five-year swings in Revenue: crashed 53.24% in 2021 and later rose 22.15% in 2024.
  • Nektar Therapeutics' Revenue stood at $25.0 million in 2021, then decreased by 11.94% to $22.0 million in 2022, then rose by 8.45% to $23.9 million in 2023, then increased by 22.15% to $29.2 million in 2024, then decreased by 25.25% to $21.8 million in 2025.
  • The last three reported values for Revenue were $21.8 million (Q4 2025), $11.8 million (Q3 2025), and $11.2 million (Q2 2025) per Business Quant data.